Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 7 of 79. Open to participants first (2,630), then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingNCT07275216Phase 2
- Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 TrialNot yet recruitingNCT07274384Phase 2
- Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid TumorsNot yet recruitingNCT07272590Phase 1/2
- Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal CancerRecruitingNCT07272382Not applicable
- A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07272291Phase 2
- PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)Not yet recruitingNCT07267234Phase 2
- A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid TumorsRecruitingNCT07266428Phase 1/2
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 StudyNot yet recruitingNCT07266025Phase 2
- A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCRecruitingNCT07264816Phase 2
- Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHNRecruitingNCT07264075Phase 3
- Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)RecruitingNCT07263919Phase 2
- A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric CancerRecruitingNCT07263386Phase 2
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Phase 1/2
- SKB264 Plus QL1706 in Recurrent or Metastatic Cervical CancerRecruitingNCT07256236Phase 2
- A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver SpreadNot yet recruitingNCT07256223Phase 2
- SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaRecruitingNCT07254585Phase 2
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingNCT07252739Phase 2
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.Not yet recruitingNCT07251062Phase 2/3
- Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLCRecruitingNCT07247227Not applicable
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCRecruitingNCT07246863Phase 2
- Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingNCT07246330Phase 3
- Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast CancerNot yet recruitingNCT07246317Phase 2
- Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid TumorsNot yet recruitingNCT07245901Phase 1/2
- A Study of Ivonescimab in First-Line ES-SCLCRecruitingNCT07245446Phase 2
- Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBCNot yet recruitingNCT07244874Phase 2
- Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaNot yet recruitingNCT07243951Phase 2
- Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular CarcinomaRecruitingNCT07243691Not applicable
- Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT07241819Phase 2
- The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical StudyRecruitingNCT07240194Phase 2
- Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomRecruitingNCT07239596Phase 1/2
- Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Phase 2
- Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI TreatmentRecruitingNCT07238881Phase 2
- Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal MelanomaNot yet recruitingNCT07236528Phase 2
- A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.RecruitingNCT07235293Phase 2
- Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain MetsNot yet recruitingNCT07234877Phase 2
- Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaRecruitingNCT07234058Phase 2
- Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerRecruitingNCT07233252Phase 2
- Iparomlimab/Tuvonralimab Injection Plus CCRT in LACCRecruitingNCT07232654Phase 2
- Neo-adjuvant Immunotherapy in Patients With Localized MelanomaRecruitingNCT07230613Phase 2
- Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With DonafenibNot yet recruitingNCT07230314Phase 2
- Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal EffusionsNot yet recruitingNCT07230301Phase 2
- A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)RecruitingNCT07229625Phase 3
- A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular CarcinomaRecruitingNCT07229417Phase 2
- Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerRecruitingNCT07228832Phase 3
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyRecruitingNCT07227636Phase 2
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingNCT07227597Phase 1/2
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingNCT07227415Phase 1/2
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.RecruitingNCT07227012Phase 1/2
- Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerRecruitingNCT07226999Phase 2/3
- BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingNCT07226856Phase 2
- Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell CancerRecruitingNCT07226544Phase 2
- Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular CancerNot yet recruitingNCT07226063Phase 2
- Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCRecruitingNCT07225374Phase 2
- Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaRecruitingNCT07223541Phase 2
- Patient Preference for Subcutaneous vs. Intravenous Immune TherapyRecruitingNCT07223424Phase 2
- Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerRecruitingNCT07222800Phase 3
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Phase 3
- Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaRecruitingNCT07221942Phase 2
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerRecruitingNCT07221357Phase 2/3
- A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)RecruitingNCT07221253Phase 3
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingNCT07221149Phase 2/3
- Retifanlimab and Ruxolitinib In Solid MalignanciesRecruitingNCT07219576Phase 1/2
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingNCT07219459Phase 2
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1
- Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal CancerNot yet recruitingNCT07214142Phase 2
- Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)RecruitingNCT07209189Phase 2
- PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaRecruitingNCT07209059Phase 2
- A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.Not yet recruitingNCT07205185Phase 2
- The IVO-LUNG StudyNot yet recruitingNCT07204548Phase 2
- A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Not yet recruitingNCT07200947Phase 2
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingNCT07198074Phase 3
- A Study of YL242 in Subjects With Advanced Solid TumorsRecruitingNCT07197827Phase 1/2
- A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer PatientsNot yet recruitingNCT07197697Phase 2
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingNCT07195734Phase 2
- Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric CancerRecruitingNCT07194005Phase 2
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingNCT07193862Early Phase 1
- Anlotinib and Benmelstobart in DTCNot yet recruitingNCT07193186Phase 2
- Adebrelimab + Apatinib in Advanced HCC Post-Systemic TherapyNot yet recruitingNCT07192848Phase 2
- Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabRecruitingNCT07192185Phase 2
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07191977Phase 2
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingNCT07188896Phase 2
- Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenRecruitingNCT07188311Not applicable
- Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast CancerRecruitingNCT07188246Phase 2
- Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell CarcinomaRecruitingNCT07188103Phase 2
- Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)RecruitingNCT07187778Phase 2
- Adjuvant Radiotherapy of Sintilimab Versus TACE for HCCRecruitingNCT07186621Phase 3
- Circulating Tumor DNA Response In Urothelial CancerRecruitingNCT07183319Phase 2
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerRecruitingNCT07180160Phase 2
- Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular CarcinomaRecruitingNCT07179900Phase 2
- Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)RecruitingNCT07179783Phase 2
- A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After TreatmentRecruitingNCT07179315Phase 2
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingNCT07178730Phase 3
- Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCCRecruitingNCT07177794Phase 3
- Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical CancerNot yet recruitingNCT07177716Phase 2/3
- Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaRecruitingNCT07177443Phase 3
- Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsRecruitingNCT07176312Phase 2
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerRecruitingNCT07174570Phase 2
- Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesRecruitingNCT07174453Phase 3
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingNCT07173751Phase 3
- Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCCRecruitingNCT07172386Phase 2